Michael Gilman, Arrakis CEO (via Obsidian)

Busy Am­gen swings an­oth­er deal, this time with RNA drug­ging play­er Ar­rakis for 'sev­er­al bil­lion'

Less than a week af­ter ink­ing a $1.9 bil­lion col­lab­o­ra­tion with Flag­ship’s Gen­er­ate to boost its AI ca­pa­bil­i­ties, Am­gen is re­turn­ing to the deal­mak­ing ta­ble.

The bio­phar­ma’s newest part­ner is Ar­rakis, as the com­pa­nies an­nounced Tues­day morn­ing they will team up to de­vel­op five RNA de­grad­er ther­a­peu­tics, with Am­gen re­tain­ing an op­tion for more. Am­gen will shell out $75 mil­lion up­front and promise “sev­er­al bil­lion dol­lars” in biobucks if all mile­stones are met, though the com­pa­ny wouldn’t pin an ex­act num­ber.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.